Galleri Trial Shows 26% Reduction in Stage IV Cancer Diagnoses, Misses Primary Endpoint
GRAL has more than doubled off its 52-week low of $29.95.
Summary
GRAIL announced full results from its NHS-Galleri trial, showing its blood test reduced Stage IV cancer diagnoses by 22% in the second round and 26% in the third. This is a significant finding for late-stage detection. However, the trial did not meet its combined primary endpoint for Stage III/IV cancers in aggregate, presenting a mixed efficacy profile. This outcome will require careful evaluation of the test's market potential and regulatory path.
At the time of this announcement, GRAL was trading at $73.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $29.95 to $118.84. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.